Last Modified: January 6, 2002
Date: May 29, 2002
Location: Patients: 2pm-7pm in the Hickey Auditorium, R11.1400 Professionals: Frank E. Anderson Lecture Hall, 11th floor, R11.1100 from 8am -1pm, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX
Symposium Web Page: multiplemyeloma.org
Sponsors: The University of Texas M.D. Anderson Cancer Center and the Multiple Myeloma Research Foundation
Who Should Attend: Hematologists, medical oncologists, internists with newly diagnosed patients, oncology nurses, patients and their families
Objectives: To learn about the latest therapies available for the treatment of Multiple Myeloma.
Conference Agenda: Patient conference held from 2pm-7pm Professional conference held from 8am-1pm
Registration Info: For patients contact Tammy Smith at the Multiple Myeloma Research Foundation 203-972-1250, email@example.com for professionals contact Christina Kirby at firstname.lastname@example.org or fax 713-794-4734 or world wide web: www.mdanderson.org/~meetings/
Fees: Physicians: early $75 regular $100 Nurses early $50 regular $75
Continuing Education: Yes
Jan 29, 2015 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Jan 29, 2015
Dec 13, 2010